header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

MANAGEMENT OF SEPTIC COMPLICATIONS FOLLOWING MODULAR ENDOPROSTHETIC RECONSTRUCTION OF THE PROXIMAL FEMUR IN CANCER PATIENTS



Abstract

The treatment of deep prosthetic infection in cancer patients with tumour prostheses remains the major complication to be dealt with in this population.

The Vienna Bone Tumour Registry includes information of more than 6500 patients of a period of 36 years. 145 patients with malignant proximal femoral tumors had resection and limb salvage with an uncemented Kotz modular femoral and tibial reconstruction megaprosthesis (KMFTR). There were twenty osteosarcomas, thirteen Ewing’s sarcomas, six chondrosarcomas, six plasmozytomas, three fibrosarcomas, three liposacomas and others. Thirteen patients (7 males, 6 females with an average age of 45 years, range 10 to 75 years) suffered from deep prosthetic infection within an average of 44 months after primary implantation, representing an infection rate of 8,97 percent.

Average follow-up was 109 months, range 7 to 339 months. Two patients with only mild signs of infection were treated by a conservative antibiotic regimen. Nine patients were treated by one-stage revision. One of the remaining two patients with severe infection underwent exarticulation of the hip as primary intervention, the other patient died due to general sepsis on the fourth post-operative day. Six patients showed no further signs of infection. Six patients, however, required one or more reoperations due to recurrent prosthetic infection. Among these four patients have successfully been treated by repeated one-stage revision, in two patients the prosthesis had to be removed permanently.

Deep prosthetic infection around modular tumour prostheses of the proximal femur and hip seems to be less common compared to distal femur, knee or tibia. However, the treatment of this complication has a higher failure rate due to multiply recurrent infection.

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org